O'Sullivan Brian, Shah Jatin
Wharton Head and Neck Center, Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada.
Semin Surg Oncol. 2003;21(1):30-42. doi: 10.1002/ssu.10019.
Cancers of the head and neck have always represented a unique perspective in cancer staging. Not only are these lesions numerous in terms of anatomic sites of origin, but, unlike most other major cancers, they frequently and readily lend themselves to adequate clinical assessment by visual inspection and palpation, which greatly facilitates documentation by the trained clinician. In addition, their location often involves treatment programs that focus on nonsurgical organ-preservation strategies, and thus anatomic and histological data for comprehensive pathologic staging are often not available. Nevertheless, the processes involved in surgical decision-making and radiotherapy treatment planning require meticulous assessment and documentation of the extent of locoregional disease. For all these reasons it is especially important to perform reliable and accurate pretreatment clinical staging of head and neck cancers. Also, many patients who succumb to head and neck cancer do so as a result of locoregional disease. Therefore, the staging system must take into account detailed local anatomic features that dictate management, since the degree of involvement of these structures by tumor may be as important as distant metastasis in threatening survival. For this reason the most recent cancer staging classification (6th edition) of the International Union Against Cancer (UICC) and the American Joint Committee on Cancer (AJCC) includes new criteria for the more advanced cases (e.g., T4 categories and stage IV disease). These criteria reflect the fact that in heterogeneous populations there is a realistic opportunity for cure in some patients but not in others. This review summarizes the criteria used in the new TNM for head and neck tumors, and outlines the rationale behind the current changes. It also provides some guidance regarding optimal source data to facilitate classification in the registry setting. In addition, the need for additional changes in the future is recognized.
头颈部癌症在癌症分期方面一直呈现出独特的视角。这些病变不仅在起源的解剖部位数量众多,而且与大多数其他主要癌症不同,它们常常且容易通过视觉检查和触诊进行充分的临床评估,这极大地方便了训练有素的临床医生进行记录。此外,其位置常常涉及侧重于非手术器官保留策略的治疗方案,因此通常无法获得用于全面病理分期的解剖学和组织学数据。然而,手术决策和放射治疗计划所涉及的过程需要对头颈部区域疾病的范围进行细致的评估和记录。出于所有这些原因,对头颈部癌症进行可靠且准确的治疗前临床分期尤为重要。而且,许多死于头颈部癌症的患者是由于局部区域疾病。因此,分期系统必须考虑到决定治疗方式的详细局部解剖特征,因为肿瘤对这些结构的累及程度在威胁生存方面可能与远处转移同样重要。出于这个原因,国际抗癌联盟(UICC)和美国癌症联合委员会(AJCC)的最新癌症分期分类(第6版)包括了针对更晚期病例(例如T4类别和IV期疾病)的新标准。这些标准反映了这样一个事实,即在异质性人群中,一些患者有实际的治愈机会,而另一些患者则没有。本综述总结了头颈部肿瘤新TNM分期所使用的标准,并概述了当前变化背后的基本原理。它还提供了一些关于最佳源数据的指导,以促进在登记处环境中的分类。此外,认识到未来还需要进一步的改变。